DexCom Overview
- Year Founded
-
1999
- Status
-
Public
- Employees
-
9,600
- Stock Symbol
-
DXCM
- Investments
-
7
- Share Price
-
$69.21
- (As of Friday Closing)
DexCom General Information
Description
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Contact Information
Website
www.dexcom.comCorporate Office
- 6340 Sequence Drive
- San Diego, CA 92121
- United States
Corporate Office
- 6340 Sequence Drive
- San Diego, CA 92121
- United States
DexCom Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $69.21 | $69.56 | $62.34 - $142.00 | $27.7B | 401M | 5.71M | $1.71 |
DexCom Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 44,782,493 | 46,840,519 | 43,500,170 | 51,227,886 |
| Revenue | 3,934,800 | 3,622,300 | 2,909,800 | 2,448,500 |
| EBITDA | 883,600 | 798,200 | 557,900 | 393,800 |
| Net Income | 666,900 | 541,500 | 341,200 | 216,900 |
| Total Assets | 6,799,200 | 6,264,500 | 5,391,700 | 4,933,300 |
| Total Debt | 2,594,300 | 2,594,000 | 2,145,000 | 2,157,900 |
DexCom Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
DexCom Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
DexCom Comparisons
Industry
Financing
Details
DexCom Competitors (14)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Senseonics | Formerly VC-backed | Germantown, MD | ||||
| Tandem Diabetes Care | Formerly VC-backed | San Diego, CA | ||||
| GlySens | Venture Capital-Backed | San Diego, CA | ||||
| GlucoWise | Formerly Accelerator/Incubator backed | London, United Kingdom | ||||
| Ascensia Diabetes Care | Formerly PE-Backed | Basel, Switzerland |
DexCom Patents
DexCom Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240340040-A1 | Systems and methods for processing and transmitting sensor data | Pending | 14-Jun-2024 | ||
| US-20240339850-A1 | Near-field-communication-based power control for an analyte sensor system | Pending | 07-Apr-2023 | ||
| US-20240335168-A1 | System and methods for personalized non-enzyme signal compensation | Pending | 07-Apr-2023 | ||
| US-20240306956-A1 | Continuous multi-analyte sensor systems | Pending | 16-Mar-2023 | ||
| US-20240275582-A1 | Wireless communication security for analyte monitoring systems | Pending | 13-Feb-2023 | H04L9/0825 |
DexCom Executive Team (52)
| Name | Title | Board Seat |
|---|---|---|
| Kevin Sayer | Chief Executive Officer, Chairman of the Board of Directors & President | |
| Jereme Sylvain | Executive Vice President and Chief Financial Officer | |
| Jake Leach | Chief Operating Officer, Operations & Executive Vice President | |
| Michael Brown JD | Executive Vice President & Chief Legal Officer, Legal | |
| Deborah Greenwood | Director, Clinical Education |
DexCom Board Members (15)
| Name | Representing | Role | Since |
|---|---|---|---|
| Bridgette Heller | Self | Board Member | |
| Eric Topol MD | Self | Board Member | |
| Karen Dahut | Self | Board Member | |
| Kevin Sayer | DexCom | Chief Executive Officer, Chairman of the Board of Directors & President | |
| Kyle Malady | Self | Board Member |
DexCom Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
DexCom Investments & Acquisitions (7)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Phenomix Sciences | 15-Apr-2024 | Other Healthcare Technology Systems | |||
| Epitel | 31-Jan-2022 | Monitoring Equipment | |||
| New Zealand Medical & Scientific | 29-Jul-2021 | Diagnostic Equipment | |||
| Beta Bionics | 09-Jan-2019 | Monitoring Equipment | |||
| TypeZero | 22-Aug-2018 | Merger/Acquisition | Other Healthcare Technology Systems |
DexCom Subsidiaries (2)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Dexcom Ventures | Corporate Venture Capital | San Diego, CA | 2021 |
| New Zealand Medical & Scientific | Diagnostic Equipment | Auckland, New Zealand |
DexCom ESG
Risk Overview
Risk Rating
Updated May, 31, 2024
21.72 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 16,009
Rank
Percentile
Healthcare
Industry
of 634
Rank
Percentile
Medical Devices
Subindustry
of 225
Rank
Percentile
DexCom FAQs
-
When was DexCom founded?
DexCom was founded in 1999.
-
Who is the CEO of DexCom?
Kevin Sayer is the CEO of DexCom.
-
Where is DexCom headquartered?
DexCom is headquartered in San Diego, CA.
-
What is the size of DexCom?
DexCom has 9,600 total employees.
-
What industry is DexCom in?
DexCom’s primary industry is Monitoring Equipment.
-
Is DexCom a private or public company?
DexCom is a Public company.
-
What is DexCom’s stock symbol?
The ticker symbol for DexCom is DXCM.
-
What is the current stock price of DexCom?
As of 11-Oct-2024 the stock price of DexCom is $69.21.
-
What is the current market cap of DexCom?
The current market capitalization of DexCom is $27.7B.
-
What is DexCom’s current revenue?
The trailing twelve month revenue for DexCom is $3.93B.
-
Who are DexCom’s competitors?
Senseonics, Tandem Diabetes Care, GlySens, GlucoWise, and Ascensia Diabetes Care are some of the 14 competitors of DexCom.
-
What is DexCom’s annual earnings per share (EPS)?
DexCom’s EPS for 12 months was $1.71.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
